[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oral-potentially-malignant-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oral-potentially-malignant-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100637326","heterogeneity-of-oral-carcinogenesis-from-preneoplasia-to-invasive-squamous-cell-carcinoma-100637326",false,"NCT07579507","Heterogeneity of Oral Carcinogenesis: From PrEneoplasia to Invasive Squamous Cell Carcinoma","HOPES","Inclusion Criteria:\n\n* I1: Male or female at least 18 years old.\n* I2: For Cohort A: patients with OSCC who undergo surgery. For cohorts B and C: patients with OPMD.\n* I3: Patient who has agreed to participate in this research and sign consent.\n* I4: Patient affiliated to a medical insurance.\n* I5: Patient who have not previously received any anticancer treatment (radiotherapy, chemotherapy, or immunotherapy)\n\nExclusion Criteria:\n\n* NI1: For cohorts B and C: Patient at high risk of bleeding, such as those receiving anticoagulant or antiplatelet therapy, those with coagulation disorders, or those with a history of severe bleeding within the two weeks prior to enrollment.\n* NI2: Pregnant or nursing woman.\n* NI3: Contraindication to general anesthesia.\n* NI4: Suspicion of rare tumor of particular histology other than squamous cell carcinoma (Sarcoma...).\n* NI5: Patient under curatorial or guardianship or placed under the protection of justice.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this project is to characterise the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and OPMD) counterparts by scRNAseq in OSCC patients. Additionally, the study will evaluate the effectiveness of non-invasive cytobrushes as a diagnostic tool compared to traditional biopsies.",[26,27],"Oral Squamous Cell Carcinomas","Oral Potentially Malignant Disorder",[29,30,31,32,33,34],"scRNAseq","Heterogeneity of all cell population","OPMD","OSCC","cytobrush","RNAseq bulk","NOT_YET_RECRUITING","2026-05-05",{"date":38,"type":39},"2026-05-12","ACTUAL",{"date":41,"type":20},"2026-06",{"date":43,"type":20},"2035-03",{"name":45,"class":46},"Centre Leon Berard","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":47},"100540758","systematical-trained-learning-algorithms-for-oral-carcinogenesis-interpretation-by-optical-coherence-tomography-100540758","NCT06321003","SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography","Single-blind Clinical Trial Assessing the Validity of Optical Coherence Tomography (OCT) in Diagnosing Potentially Malignant Oral Lesions and Oral Cancer","SYMILIS OCT","Inclusion Criteria:\n\n1. Adult patients with clinical suspicion of potentially malignant oral disorders (OPMDs) and oral squamous cell carcinoma (OSCC).\n2. Patients able to provide informed consent for participation in the study.\n3. Availability of complete clinical data and medical records.\n\nExclusion Criteria:\n\n1. Patients with a previous diagnosis of OSCC\u002FOPMDs and\u002For who have already undergone treatment.\n2. Patients with contraindications to the OCT examination for nonpermissive oral localization using the probe.\n3. Pregnant or breastfeeding women.\n4. Patients with disabilities, reluctance or difficulties of understanding to follow the procedures of the study and who have not provided a consent.","99 Years",{"count":58,"type":20},200,"OBSERVATIONAL","This clinical trial aims to assess the efficacy of Optical Coherence Tomography (OCT) in the early diagnosis of oral cancer. It focuses on Oral Potentially Malignant Disorders (OPMDs) as precursors to Oral Squamous Cell Carcinoma (OSCC). Despite the availability of oral screening, diagnostic delays persist, underscoring the importance of exploring non-invasive methodologies. The OCT technology provides cross-sectional analysis of biological tissues, enabling a detailed evaluation of ultrastructural oral mucosal features.\n\nThe trial aims to compare OCT preliminary evaluation with traditional histology, considered the gold standard in oral lesion diagnosing. It seeks to create a database of pathological OCT data, facilitating the non invasive identification of carcinogenic processes. The goal is to develop a diagnostic algorithm based on OCT, enhancing its ability to detect characteristic patterns such as the keratinized layer, squamous epithelium, basement membrane, and lamina propria in oral tissues affected by OPMDs and OSCC.\n\nFurthermore, the trial aims to implement Artificial Intelligence (AI) in OCT image analysis. The use of machine learning algorithms could contribute to a faster and more accurate assessment of images, aiding in early diagnosis. The trial aims to standardize the comparison between in vivo OCT images and histological analysis, adopting a site-specific approach in biopsies to improve correspondence between data collected by both methods.\n\nIn summary, the trial not only evaluates OCT as a diagnostic tool but also aims to integrate AI to develop a standardized approach that enhances the accuracy of oral cancer diagnosis, providing a significant contribution to clinical practice.",[62,27,63,64,65,66,67,68,69,70,71,72],"Oral Squamous Cell Carcinoma","Oral Leukoplakia","Proliferative Verrucous Leukoplakia","Oral Lichen Planus","Oral Lichenoid Lesion","Graft-versus-host-disease","Oral Erythroplakia","Actinic Keratoses","Actinic Cheilitis","Oral Cancer","Oral Disease","RECRUITING","2025-05-19",{"date":76,"type":39},"2025-05-23",{"date":78,"type":39},"2024-03-13",{"date":80,"type":20},"2028-04-01",{"name":82,"class":46},"University of Palermo",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":93,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":47},"100549814","nbi-for-early-diagnosis-of-opmdoscc-100549814","NCT06438939","NBI for Early Diagnosis of OPMD\u002FOSCC","Narrow Band Imaging (NBI) for Early Diagnosis of Oral Squamous Cell Carcinoma (OSCC) and Oral Potentially Malignant Disorders (OPMD)","NBI_Oral","Inclusion Criteria:\n\n* Patients with soft tissue, mucosal lesions of the oral cavity, who arrive for an initial first diagnosis (group 1);\n* Patients with history OPMD (clinically evident lesion\u002Fs group 2a, lesion\u002Fs excised group 2b), who are in follow-up (OPMDs included are eg. Leukoplakia, erythroleukoplakia, erythroplakia, oral lichen planus, oral lichenoid lesion);\n* Patients with history of HNSCC (OSCC group 3a, sinonasal, nasopharynx, oropharynx, larynx, oesophagus group 3b);\n* High risk (see above) individuals with no known oral mucosal disease (group 4);\n\nExclusion Criteria:\n\n* patients who did not need a biopsy nor after WLOE (e.g. normal mucosa, anatomical variation) nor after NBI (pattern I)\n* patients who, despite indication, were not suitable to undergo biopsy given his \u002F her systemic conditions",{"count":92,"type":20},480,[23],"Early detection - possibly at its pre-malignant stages (Oral Potentially Malignant Disorders, OPMD) - with periodic surveillance is thus fundamental for limiting disease burden, hopefully reducing the incidence of advanced stages OSCC and increasing survival. Narrow Band Imaging (NBI) has proved itself as promising tool for helping clinician both for diagnosis and therapy. Yet, there is no definitive scientific evidence that NBI is superior to common oral examination with white light (WLOE) for diagnosing OSCC\u002FOPMD. We thus propose a randomised clinical trial understand its role in this field.",[62,27],[97,32,31,98],"narrow band imaging","NBI","2024-05-27",{"date":101,"type":39},"2024-06-03",{"date":103,"type":20},"2024-09-30",{"date":105,"type":20},"2026-12-31",{"name":107,"class":46},"Cardarelli Hospital"]